Header Logo

Connection

JENNIFER WARGO to Melanoma

Back to Details
This is a "connection" page, showing publications JENNIFER WARGO has written about Melanoma.
JENNIFER WARGO
Connection Strength
8.182
Melanoma
  1. Neoadjuvant therapy for melanoma: new and evolving concepts. Clin Adv Hematol Oncol. 2022 Jan; 20(1):47-55.
    View in: PubMed
    Score: 0.236
  2. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.235
  3. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.233
  4. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep. 2020 06 24; 22(7):74.
    View in: PubMed
    Score: 0.212
  5. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Ann Surg Oncol. 2020 May; 27(5):1533-1545.
    View in: PubMed
    Score: 0.206
  6. Neoadjuvant therapy for melanoma: is it ready for prime time? Lancet Oncol. 2019 07; 20(7):892-894.
    View in: PubMed
    Score: 0.197
  7. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:197-207.
    View in: PubMed
    Score: 0.183
  8. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.179
  9. Cancer Evolution during Immunotherapy. Cell. 2017 11 02; 171(4):740-742.
    View in: PubMed
    Score: 0.176
  10. Interaction of molecular alterations with immune response in melanoma. Cancer. 2017 06 01; 123(S11):2130-2142.
    View in: PubMed
    Score: 0.171
  11. Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer. 2017; 5:10.
    View in: PubMed
    Score: 0.168
  12. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res. 2015 Jul 15; 21(14):3102-4.
    View in: PubMed
    Score: 0.149
  13. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.138
  14. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 01; 70(13):5213-9.
    View in: PubMed
    Score: 0.106
  15. Surgical management of melanoma. Hematol Oncol Clin North Am. 2009 Jun; 23(3):565-81, x.
    View in: PubMed
    Score: 0.098
  16. Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer. 2024 Dec 04; 24(1):1493.
    View in: PubMed
    Score: 0.072
  17. Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
    View in: PubMed
    Score: 0.072
  18. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov. 2024 Jul 01; 14(7):1161-1175.
    View in: PubMed
    Score: 0.070
  19. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun. 2024 Feb 07; 15(1):1148.
    View in: PubMed
    Score: 0.068
  20. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.
    View in: PubMed
    Score: 0.066
  21. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 09; 34(9):796-805.
    View in: PubMed
    Score: 0.065
  22. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
    View in: PubMed
    Score: 0.065
  23. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 05; 617(7960):377-385.
    View in: PubMed
    Score: 0.065
  24. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol. 2023 Aug; 128(2):313-321.
    View in: PubMed
    Score: 0.064
  25. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
    View in: PubMed
    Score: 0.064
  26. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.064
  27. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 02; 4(2):222-239.
    View in: PubMed
    Score: 0.063
  28. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
    View in: PubMed
    Score: 0.063
  29. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.062
  30. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022 11; 28(11):2344-2352.
    View in: PubMed
    Score: 0.062
  31. Multi-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000.
    View in: PubMed
    Score: 0.061
  32. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.061
  33. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):437-445.
    View in: PubMed
    Score: 0.060
  34. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 03 01; 10(3):303-313.
    View in: PubMed
    Score: 0.060
  35. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 02 15; 3(2):100500.
    View in: PubMed
    Score: 0.059
  36. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022 04; 22(4):195-207.
    View in: PubMed
    Score: 0.059
  37. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708.
    View in: PubMed
    Score: 0.059
  38. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3.
    View in: PubMed
    Score: 0.059
  39. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729.
    View in: PubMed
    Score: 0.059
  40. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031.
    View in: PubMed
    Score: 0.057
  41. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489.
    View in: PubMed
    Score: 0.056
  42. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021 04; 592(7852):138-143.
    View in: PubMed
    Score: 0.056
  43. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 02; 27(2):301-309.
    View in: PubMed
    Score: 0.055
  44. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. 2021 02; 590(7845):332-337.
    View in: PubMed
    Score: 0.055
  45. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 02 05; 371(6529):602-609.
    View in: PubMed
    Score: 0.055
  46. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. Clin Cancer Res. 2021 01 15; 27(2):394-401.
    View in: PubMed
    Score: 0.054
  47. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579.
    View in: PubMed
    Score: 0.053
  48. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 06 17; 41(4):452-457.
    View in: PubMed
    Score: 0.053
  49. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
    View in: PubMed
    Score: 0.052
  50. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020 02 12; 11(1):853.
    View in: PubMed
    Score: 0.052
  51. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
    View in: PubMed
    Score: 0.052
  52. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.052
  53. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565.
    View in: PubMed
    Score: 0.051
  54. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.051
  55. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.050
  56. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
    View in: PubMed
    Score: 0.050
  57. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019 11; 139(11):2352-2358.e3.
    View in: PubMed
    Score: 0.049
  58. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.048
  59. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
    View in: PubMed
    Score: 0.048
  60. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
    View in: PubMed
    Score: 0.047
  61. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma. Pigment Cell Melanoma Res. 2019 03; 32(2):280-291.
    View in: PubMed
    Score: 0.047
  62. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.047
  63. Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov. 2019 01; 9(1):64-81.
    View in: PubMed
    Score: 0.047
  64. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov. 2018 11; 8(11):1366-1375.
    View in: PubMed
    Score: 0.047
  65. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.
    View in: PubMed
    Score: 0.046
  66. Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity. 2018 06 19; 48(6):1077-1080.
    View in: PubMed
    Score: 0.046
  67. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.046
  68. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 2018 Jul; 45(7):545-549.
    View in: PubMed
    Score: 0.046
  69. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
    View in: PubMed
    Score: 0.045
  70. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018 02 12; 6(1):14.
    View in: PubMed
    Score: 0.045
  71. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.045
  72. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 11 16; 15(1):236.
    View in: PubMed
    Score: 0.044
  73. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep. 2017 Nov 14; 21(7):1936-1952.
    View in: PubMed
    Score: 0.044
  74. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep. 2017 Nov 14; 21(7):1953-1967.
    View in: PubMed
    Score: 0.044
  75. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.044
  76. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017 09 19; 8(1):607.
    View in: PubMed
    Score: 0.044
  77. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
    View in: PubMed
    Score: 0.043
  78. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017 08; 9(8):1011-1029.
    View in: PubMed
    Score: 0.043
  79. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov. 2017 08; 7(8):832-851.
    View in: PubMed
    Score: 0.043
  80. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017 06 05; 214(6):1691-1710.
    View in: PubMed
    Score: 0.043
  81. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692.
    View in: PubMed
    Score: 0.043
  82. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.043
  83. Point of care assessment of melanoma tumor signaling and metastatic burden from ?NMR analysis of tumor fine needle aspirates and peripheral blood. Nanomedicine. 2017 04; 13(3):821-828.
    View in: PubMed
    Score: 0.042
  84. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.041
  85. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
    View in: PubMed
    Score: 0.041
  86. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.041
  87. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
    View in: PubMed
    Score: 0.041
  88. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.040
  89. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454.
    View in: PubMed
    Score: 0.040
  90. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.040
  91. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.
    View in: PubMed
    Score: 0.040
  92. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4.
    View in: PubMed
    Score: 0.040
  93. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016 05 02; 126(5):1834-56.
    View in: PubMed
    Score: 0.040
  94. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
    View in: PubMed
    Score: 0.039
  95. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 08 01; 122(15):2299-312.
    View in: PubMed
    Score: 0.039
  96. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016 Mar 14; 29(3):270-284.
    View in: PubMed
    Score: 0.039
  97. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Oncotarget. 2016 Feb 09; 7(6):6448-59.
    View in: PubMed
    Score: 0.039
  98. Novel Treatments in Development for Melanoma. Cancer Treat Res. 2016; 167:371-416.
    View in: PubMed
    Score: 0.039
  99. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.039
  100. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310.
    View in: PubMed
    Score: 0.038
  101. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 2015 Dec; 135(12):3115-3124.
    View in: PubMed
    Score: 0.038
  102. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10; 35(10):1225-35.
    View in: PubMed
    Score: 0.037
  103. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015 Jun 09; 11(9):1458-73.
    View in: PubMed
    Score: 0.037
  104. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.037
  105. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.037
  106. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
    View in: PubMed
    Score: 0.037
  107. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
    View in: PubMed
    Score: 0.036
  108. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.
    View in: PubMed
    Score: 0.036
  109. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8.
    View in: PubMed
    Score: 0.036
  110. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 01; 74(23):7037-47.
    View in: PubMed
    Score: 0.036
  111. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
    View in: PubMed
    Score: 0.036
  112. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
    View in: PubMed
    Score: 0.035
  113. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
    View in: PubMed
    Score: 0.035
  114. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
    View in: PubMed
    Score: 0.034
  115. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
    View in: PubMed
    Score: 0.034
  116. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93.
    View in: PubMed
    Score: 0.033
  117. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.
    View in: PubMed
    Score: 0.033
  118. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med. 2013 Jul 11; 369(2):173-83.
    View in: PubMed
    Score: 0.033
  119. Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell. 2013 Mar 18; 23(3):302-15.
    View in: PubMed
    Score: 0.032
  120. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6.
    View in: PubMed
    Score: 0.032
  121. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.032
  122. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.031
  123. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49.
    View in: PubMed
    Score: 0.031
  124. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53.
    View in: PubMed
    Score: 0.031
  125. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013 Feb 01; 19(3):598-609.
    View in: PubMed
    Score: 0.031
  126. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.
    View in: PubMed
    Score: 0.031
  127. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
    View in: PubMed
    Score: 0.031
  128. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4.
    View in: PubMed
    Score: 0.031
  129. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.031
  130. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.030
  131. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67.
    View in: PubMed
    Score: 0.018
  132. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021 10 14; 184(21):5338-5356.e21.
    View in: PubMed
    Score: 0.014
  133. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.014
  134. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 01 12; 12(1):346.
    View in: PubMed
    Score: 0.014
  135. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
    View in: PubMed
    Score: 0.013
  136. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238.
    View in: PubMed
    Score: 0.012
  137. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.011
  138. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872.
    View in: PubMed
    Score: 0.009
  139. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa. Cancer Discov. 2014 Oct; 4(10):1214-1229.
    View in: PubMed
    Score: 0.009
  140. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery. 2013 Dec; 154(6):1456-62; discussion 1462.
    View in: PubMed
    Score: 0.008
  141. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013 Dec 05; 504(7478):138-42.
    View in: PubMed
    Score: 0.008
  142. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90.
    View in: PubMed
    Score: 0.007
  143. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 2011 Jan 15; 186(2):685-96.
    View in: PubMed
    Score: 0.007
  144. Metastatic tumors in the pancreas in the modern era. J Am Coll Surg. 2010 Dec; 211(6):749-53.
    View in: PubMed
    Score: 0.007
  145. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.